ĀÜĄņĀŅĀ×

Dr. Julien Mamet joined Exalys in July 2020 as Chief Scientific Officer. Prior to Exalys, Dr. Julien Mamet founded Adynxx, a developer of non-opioid pain therapeutics in 2007. He served as Chief Executive Officer and President until 2010 and as Chief Scientific Officer until 2020.

Julien has extensive pharmaceutical experience in the areas of neuroscience and drug discovery and is the inventor of the AYX transcription factor decoy technology platform developed by Adynxx. Prior to Adynxx, he worked at the SCRIPPS Research Institute and Novartis Genomics Institute in San Diego, California.

Julien obtained his Ph.D. in Pain and Pharmacology at the Institute of Molecular and Cellular Pharmacology in Nice-Sophia Antipolis, France, where he worked in the laboratory of Prof. Michel Lazdunski, a worldwide leader in pain research with over 600 publications in the field. His graduate work focused on the identification and validation of novel targets for pain drug therapies. In parallel to his PhD work, he taught biochemistry Mastersā€™ courses at the University of Nice-Sophia Antipolis, France. Julien obtained his BS and MS in Pharmacology and Genetics at the University Claude Bernard in Lyon, France.